جست‌وجوی استاد و پژوهشگر

David J. Samuelsonمشاهده پروفایل

استاد

• Breast Cancer Susceptibility
• Cancer Prevention
• Quantitative Trait Loci (QTL) Mapping
• +۳ مورد دیگر

David J. Samuelson, Ph.D. , is a faculty member in the Department of Biochemistry and Molecular Genetics , where he leads a research program devoted to understanding the genetic basis of breast cancer susceptibility and prevention. His laboratory employs rat models and comparative genomics to identify quantitative trait loci (QTLs) and unravel the molecular mechanisms governing mammary carcinoma risk. Education: Ph.D., 2001, University of Arizona, Tucson, AZ Postdoctoral Training, McArdle Laboratory for Cancer Research, University of Wisconsin–Madison, Madison, WI Research Interests Dr. Samuelson’s work centers on breast cancer susceptibility and prevention . Using congenic rat strains, he maps and functionally characterizes mammary carcinoma susceptibility (Mcs) loci, translating findings to human orthologous regions through integrative genomics. His studies dissect the roles of non-coding regulatory elements, immune modulation, and environmental interactions in cancer risk. Publication Trends Across 23 peer-reviewed articles (1995–2023), Samuelson’s research has progressively focused on: Identification and fine-mapping of rat Mcs QTLs (Mcs1–Mcs6). Comparative genomics aligning rat susceptibility loci with human GWAS hits. Functional validation of candidate genes such as FBXO10 , MIER3 , and Tenascin C . Development of pre-clinical models for testing preventive interventions. Laboratory Team Emily Duderstadt, B.S. – Ph.D. Candidate Sarah McQuaide – Research Technician

Lopa Das Royمشاهده پروفایل

دانشیار مدعو

• Breast Cancer Research
• Immunology
• Cancer Metastasis
• +۴ مورد دیگر

Lopa Das Roy, Ph.D., is an Adjunct Associate Professor at the University of North Carolina at Charlotte (UNCC) and Research Director at OncoTab Inc. She holds a Doctoral Degree in Genetics from Assam University (2007) and has extensive postdoctoral experience at the Mayo Clinic and UNCC. Her research focuses on cancer metastasis mechanisms, particularly the interplay between arthritis and breast cancer progression, as well as the role of MUC1 protein in pancreatic cancer. Education: Ph.D. in Genetics, Assam University, India (2007) Postdoctoral Fellowships: Mayo Clinic (2007–2008), UNCC (2008–2010) Research Interests: Her work explores cancer metastasis pathways, inflammatory links to cancer, and therapeutic targeting of oncogenes like MUC1. Key areas include: Arthritis-driven breast cancer metastasis MUC1-mediated pancreatic cancer progression Therapeutic strategies for drug-resistant cancers Publications and Media: Her research has been featured in high-impact journals (e.g., Oncogene , Breast Cancer Research ) and widely covered in news outlets due to breakthroughs like identifying the SCF/c-Kit signaling link in arthritis-related metastasis (2012). Awards and Grants: Department of Defense (DOD) Postdoctoral Grant (2009–2012) Highly accessed articles in Breast Cancer Research and BMC journals AACR Annual Meeting Newsworthy Recognition (2012) Academic Service: She serves on grant review committees, chairs conferences (e.g., 2015 Global Cancer Summit), and mentors students in cancer research.

• Hematology
• Molecular Biology
• Carcinogenesis
• +۳ مورد دیگر

Roger Mulet Lázaro is a Researcher at the Hematology department of Erasmus University Medical Center. His work focuses on molecular mechanisms underlying hematologic malignancies, with particular expertise in enhancer regions, epigenetic regulation, and oncogenic pathways. Key research areas include GATA2 deficiency syndromes, MYC dysregulation in lymphomas, and the role of cohesin in leukemia. Collaborations span international teams addressing genetic and epigenetic drivers of blood cancers Recent contributions highlight novel insights into somatic mutations in myelodysplastic syndromes and VEGF signaling in AML His review articles synthesize current knowledge on enhancer-driven oncogenesis and STAG2 mutation impact in AML pathogenesis. Research outputs show significant engagement with cutting-edge genomic and epigenomic approaches.

Bruno Melilloمشاهده پروفایل

پژوهشگر

• Chemical Biology
• Drug Development
• Antimicrobial Agents
• +۷ مورد دیگر

Bruno Melillo is an Institute Investigator in the Department of Chemistry. He holds a PhD from the University of Pennsylvania (2015), an M.Sc. from Université Pierre-et-Marie-Curie (2010), and a Diplôme d'Ingénieur from ESPCI Paris-PSL (2010). His postdoctoral work (2017) was conducted at the Broad Institute of MIT and Harvard. His research focuses on chemical biology, drug development for parasitic diseases, HIV/AIDS, and cancer. Key areas include covalent ligand design, proteomic mapping, small molecule inhibitors, and antiparasitic agent synthesis. His work merges organic synthesis with biological systems to address unmet medical needs in infectious diseases and oncology. Recent studies highlight innovations in azetidine library synthesis for antimalarial agents, structural analysis of HIV entry mechanisms, and covalent targeting of oncogenic proteins. His technical expertise spans diversity-oriented synthesis, photoreactive probes, and proteomic profiling. Though no formal grants or awards are listed, his publication record demonstrates impactful contributions to chemical biology and translational medicine. Current projects likely involve expanding the ligandable proteome and developing next-generation therapeutics.

Pirooz Poursoltanمشاهده پروفایل

دانشیار بالینی

• Medical Oncology
• Cancer Genetics
• Lung Cancer
• +۵ مورد دیگر

Pirooz Poursoltan is an Associate Professor and Clinical Associate Professor at Macquarie University's Macquarie Medical School, where he serves as Head of the Medical Oncology Discipline. He is a practicing medical oncologist specializing in lung, gastrointestinal, and breast cancers, with over a decade of clinical experience. His research focuses on molecular changes in lung cancer, novel anticancer agents, and phase I-III clinical trials. He contributes to medical education by lecturing in the MD program on topics like cancer management, genetics, and oncology training. Education: Holds a Master's degree in Medicine. Research Interests: Molecular oncology, targeted therapies, cancer genetics, and translational research. He collaborates with laboratory teams to develop new treatments and has led multiple clinical trials including the OXTOX study (2021-2026) and DYNAMIC III (2019-2024). Collaborations: Active in multi-institutional studies involving cardiology, genetics, and oncology. Notable projects include early cardiotoxicity detection via echocardiography and trials assessing ibudilast for oxaliplatin neurotoxicity reduction. Grants & Projects: Principal investigator on 5 projects totaling AUD millions in funding. Labs/Teams: Collaborates with Macquarie肿瘤学团队 and跨学科研究小组在开发新型疗法方面.

Anke van den Bergمشاهده پروفایل

استاد

• Molecular pathogenesis of B-cell lymphoma
• Noncoding RNAs
• Hodgkin lymphoma
• +۵ مورد دیگر

Prof. Anke van den Berg is a Professor of Molecular Pathogenesis of Malignant B-Cell Lymphoma at the University of Groningen's Faculty of Medical Sciences. She holds positions as a Clinical Molecular Biologist in Pathology at the UMCG, and leads research within the Stem cells, Aging, Leukemia and Lymphoma (SALL) program. Her work focuses on noncoding RNAs, genomic aberrations, and therapy resistance in lymphomas. She supervises PhD students and sits on editorial and review committees. Education: PhD (cum laude) in Molecular Pathology (1996), followed by postdoctoral roles and academic promotions. Research funding comes from KWF, EU, NWO, and SKOG. Research interests include Hodgkin/non-Hodgkin lymphoma pathogenesis, microRNA roles, and molecular diagnostics. She develops biomarkers for therapy guidance and investigates targeted therapies in lung cancer. Her lab is part of the North Netherlands Oncology Center (NNOC). Awards: Not explicitly listed, but her work has received significant research grants and international collaborations. Advising/Grants: Supervised 45+ PhDs, oversees multiple funded projects, and collaborates globally. Active in professional roles like ZonMW review committees and MicroRNA editorial boards. Labs/Teams: Leads the Lymphoma Research Group Groningen and collaborates with Translational Immunology Groningen (TRIGR) and Molecular Oncology (MO) teams.

Ashley Lakodukمشاهده پروفایل

عضو هیئت علمی

• Molecular Biology
• Cell Biology
• Biochemistry and Biophysics
• +۲ مورد دیگر

Ashley Lakoduk is an Assistant Professor of Instruction in the Department of Biological Sciences at The University of Texas at Dallas (UT Dallas), within the School of Natural Sciences and Mathematics. Her research focuses on molecular mechanisms of endocytic pathways, mutant p53 signaling in cancer, and integrin trafficking. She holds a PhD in Biomedical Sciences from UT Southwestern Medical Center (2019), and prior degrees from UC San Diego (MS 2012, BS 2008). She is affiliated with professional organizations including the American Society for Cell Biology (ASCB), AAAS, and ASBMB. Her work bridges basic cell biology with translational cancer research, emphasizing microscopy-based approaches and science communication. Currently, she is not accepting undergraduate students but actively publishes on endocytic dynamics and cancer cell migration mechanisms. Educations: PhD in Biomedical Sciences (Cell and Molecular Biology), UT Southwestern Medical Center (2019) MS in Biology, UC San Diego (2012) BS in Molecular Biology, UC San Diego (2008) Her research interests center on understanding how endocytic pathways regulate cancer cell behavior, particularly through mutant p53-driven signaling and integrin recycling. She employs quantitative microscopy and systems biology approaches to dissect these molecular networks. Her publications since 2015 have explored topics such as dynamin/APPL1 feedback loops, EGFR/Akt signaling, and T-cell signaling condensates. She emphasizes science communication as part of her professional identity. Publications highlight her focus on endosomal trafficking, cancer-related signaling pathways, and developing experimental tools like single-chain antibodies for live-cell imaging. Recent work (2021) investigates novel endocytic functions in mutant p53 cancer cells, linking cellular trafficking to oncogenic migration. Professional memberships include ASCB, AAAS, and ASBMB. No current grants or lab details are specified in the text, though her educational role suggests involvement in undergraduate/graduate instruction in biological sciences.

Xiaoqi Liuمشاهده پروفایل

استاد

• Cancer Biology
• Molecular Oncology
• Toxicology
• +۷ مورد دیگر

Xiaoqi Liu, PhD, is a Professor and Chair in the Department of Toxicology and Cancer Biology at the University of Kentucky, where he also holds the Lucille P. Markey Endowed Chair in Oncology Research. His research focuses on understanding the molecular basis of cancer to develop novel targeted therapies. Research Interests: Molecular mechanisms of oncogenesis Polo-like kinase 1 (Plk1) signaling in cancer Chemoresistance and DNA damage response Targeted therapy for prostate, pancreatic, lung cancers, and melanoma Combination therapies involving kinase inhibitors and epigenetic drugs His recent publications highlight a strong focus on Plk1’s role in regulating tumor suppressors (PTEN, TSC1, Numb), DNA repair proteins (Mre11, MDC1), and its potential to enhance the efficacy of PARP, BET, and mTOR inhibitors. The work spans molecular oncology, cell signaling, and preclinical therapeutic development. Scientific Awards and Honors: Lucille P. Markey Endowed Chair in Oncology Research Xiaoqi Liu leads an active research laboratory investigating Plk1 as a therapeutic target. While specific grant details and student mentorship are not listed, his extensive publication record and leadership role suggest a well-funded and productive research program. The LIU Research Lab uses biochemistry, cell biology, and mouse genetics to explore cancer mechanisms and treatment strategies.

Diane F. Jelinekمشاهده پروفایل

استاد

• Immunology
• B Cell Biology
• Plasma Cell Biology
• +۱۲ مورد دیگر

Diane F. Jelinek, Ph.D., is a Professor of Immunology at Mayo Clinic, with appointments in the Department of Research (Division of Cellular Immunology) and the Department of Internal Medicine (Division of Hematology). She is based in Phoenix, Arizona, and leads a research laboratory focused on B cell and plasma cell biology and their roles in malignancies such as chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and primary amyloidosis. She previously served as Dean of Research at Mayo Clinic in Arizona from 2015 to 2022 and holds the Gene and Mary Lou Kurtz Professorship in Multiple Myeloma Research. Her research explores the molecular mechanisms of B cell survival, differentiation, and oncogenesis. Key areas include B cell receptor signaling, activation-induced cytidine deaminase (AID), toll-like receptors, cytokine receptors, and CD40 ligand interactions. Her lab uses next-generation sequencing to analyze antibody gene repertoires and studies metabolic reprogramming in premalignant plasma cell disorders like monoclonal gammopathy of undetermined significance (MGUS). She has characterized B cell antigen receptors in over 2,000 CLL patients and investigates gene expression profiles to understand disease heterogeneity. The recent publications highlight a strong trend in genomic and molecular analysis of B cell cancers, particularly focusing on CLL and myeloma. Her work integrates clinical data with molecular profiling, emphasizing biomarker discovery, metabolic changes, and immune microenvironment dynamics. She is actively involved in translational research with implications for therapeutic targeting. Gene and Mary Lou Kurtz Professor of Multiple Myeloma Research (2008) Diane F. Jelinek has led multiple NIH-funded research projects, including the Mayo Clinic Multiple Myeloma SPORE as a Co-Principal Investigator and several NCI-funded grants as Principal Investigator. Her lab has trained numerous researchers and collaborates extensively within the Mayo Clinic Comprehensive Cancer Center and David F. and Margaret T. Grohne Cancer Immunology and Immunotherapeutics Program. She has not advised any named students in the provided text, but her leadership in large collaborative studies indicates significant mentorship roles. Her laboratory is integral to the Immunology Research program at Mayo Clinic and contributes to the Robert and Arlene Kogod Center on Aging. The lab utilizes patient-derived tumor cells and established myeloma cell lines to study disease progression and therapeutic responses. She is actively engaged in both basic and clinical research teams focused on cancer immunology and hematologic malignancies.

Marta Gagliaمشاهده پروفایل

دانشیار

• Virology
• Molecular Virology
• Host-Pathogen Interactions
• +۱۳ مورد دیگر

Marta Gaglia is an Associate Professor in the Department of Medical Microbiology and Immunology at the University of Wisconsin–Madison, School of Medicine and Public Health, and a member of the Institute for Molecular Virology and the Carbone Cancer Center. She leads an active research laboratory focused on virus-host interactions, particularly in influenza A virus and Kaposi’s sarcoma-associated herpesvirus (KSHV). Her lab relocated from Tufts University to UW–Madison in fall 2022, where she continues to mentor graduate students, postdoctoral researchers, and undergraduates. Her research centers on how viruses manipulate host innate immune responses, such as the cGAS/STING and interferon pathways, and how viral proteins like PA-X and ORF42 induce host shutoff and immune evasion. By studying both RNA and DNA viruses, her lab identifies conserved and unique mechanisms of viral subversion. The recent publications from her lab demonstrate a strong focus on molecular mechanisms of viral gene regulation, RNA degradation, and immune modulation. Her work combines biochemical, transcriptomic, and virological approaches to link molecular events to disease outcomes. Her scientific achievements have been recognized with awards such as the Ann Palmenberg Junior Faculty Award (2019) . Marta Gaglia mentors a diverse team of trainees and is a trainer in the Microbiology Doctoral Training Program (MDTP) and the Cell and Molecular Biology (CMB) program. Her lab has secured competitive grants, including an R01, supporting ongoing research. She fosters a collaborative and supportive lab culture, emphasizing mentorship and scientific excellence. The Gaglia Lab is actively involved in scientific outreach and community engagement, including participation in events during the pandemic and professional conferences. They also maintain a strong lab identity through team-building activities and celebrations of scientific milestones.

Gary Hardimanمشاهده پروفایل

استاد

• Systems Biology
• Multi-Omics Data Integration
• Prostate Cancer Research
• +۷ مورد دیگر

Professor Gary Hardiman is a faculty member at Queen's University Belfast, holding the rank of Professor in the School of Biological Sciences under the Faculty of Medicine, Health and Life Sciences. He is affiliated with the Institute for Global Food Security and maintains an active research program with office location at Room 0G.107, Biological Sciences building in Belfast, United Kingdom. His work focuses on systems biology and computational approaches to complex health and environmental challenges, with recent media coverage highlighting applications in space travel research. Research interests include: Systems biology and multi-omics data integration for genotype-phenotype prediction Effects of microplastics and persistent organic pollutants on marine ecosystems and human health Racial disparities in prostate cancer linked to vitamin D deficiency and BAZ1A regulation Physiological impacts of space radiation, microgravity, and torpor on hepatic/intestinal biology Rat models for opioid abuse vulnerability and neuronal correlates of addiction His publication trends (2023-2025) emphasize prostate cancer disparities, space biology mechanisms, and microplastics toxicity using computational frameworks. Key methodologies involve network pharmacology, multi-omics integration, and cross-species modeling (mice, rats, zebrafish) to address UN Sustainable Development Goals in health and environmental protection. Scientific Awards: No specific awards or honors were documented in the provided text Advising and Grants: Hardiman actively supervises PhD students with 10 supervised works recorded, accepting new applicants in computer science, bioinformatics, biochemistry, microbiology, or marine biology requiring funding strategies. He serves as Principal Investigator for R5254GFS (microplastics characterization) and Co-Investigator for R1499PSY (PTSD research) and R1906ECS (proteoform peptide index). Additional funding includes an NIH U01 grant for opioid dependence research at Medical University of South Carolina, demonstrating substantial grant acquisition in environmental health and biomedical fields. Labs and Teams: He leads research within Queen's University Belfast's Institute for Global Food Security, collaborating with international teams from University of California, Medical University of South Carolina, Wake Forest School of Medicine (USA), Università di Camerino (Italy), National University of Ireland Galway, and University of Aberdeen (Scotland). These partnerships focus on space omics, environmental contaminants, and cancer disparities using systems biology toolkits. His group contributes to the European Space Agency's space biology initiatives and develops computational models for public health risk assessment.

Lopa Mishraمشاهده پروفایل

استاد مدعو

• Translational Medicine
• Bioelectronic Medicine
• Gastrointestinal Cancers
• +۱۱ مورد دیگر

Lopa Mishra, MD, is an Adjunct Professor and Co-Director of the Institute of Bioelectronic Medicine at the Feinstein Institutes for Medical Research, affiliated with the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. She holds the Susan and Herman Merinoff Distinguished Chair in Translational Medicine and co-leads the institute with Dr. Yousef Al-Abed. Her career includes prior leadership roles as Chair of Gastroenterology at MD Anderson Cancer Center and Director of the Center for Translational Medicine at George Washington University. Her research focuses on the continuum of science-driven clinical care, particularly in gastrointestinal cancers, liver disease, metabolism, obesity, addiction, inflammatory bowel disease, and bioelectronic medicine. Her work emphasizes the role of TGF-β signaling in cancer and stem cell disorders, aiming to develop novel therapies and improve clinical outcomes. The recent publications highlight a strong focus on TGF-β pathway dysregulation in cancer, epigenetic mechanisms in Beckwith-Wiedemann syndrome, microbiome interactions in colorectal cancer, and pan-cancer genomic analyses. Her research integrates molecular biology, genetics, and translational approaches to understand disease mechanisms and identify therapeutic targets. Scientific Awards: AACR Team Science Award (2020) Elaine H. Snyder Cancer Research Award (2019) Elected Member, Association of American Physicians (2019) Councilor-at-Large, AASLD (2016-2019) Fellow, AAAS (2016) Fellow, AASLD (2014) IACGH Award for Health Initiation in Houston (2011) AGA Award for Top Women in Gastroenterology (2008) Member, ASCI (2003) Dr. Mishra has a strong record of mentoring and advising, having cultivated educational programs that developed physician-scientists at multiple institutions. She has served on advisory boards for UCLA, Mayo Clinic, VCU, Cincinnati, and Georgetown University. Her leadership includes chairing sessions at national meetings, delivering invited talks, and co-authoring numerous high-impact publications. She is currently developing new studies at the intersection of obesity, fibrosis, and cancer. Lab Members: Kazufumi Ohshiro – Assistant Investigator Shuyun Rao – Assistant Professor Xiyan Xiang – Postdoc Research Trainee Xiaochun Yang – Postdoc Research Trainee Sobia Zaidi – Postdoc Research Trainee

• Cell Biology
• Molecular Biology
• Developmental Biology
• +۳ مورد دیگر

Yicktung Ip is a Professor at the T.H. Chan School of Medicine , specializing in Program in Molecular Medicine at UMass Chan Medical School. His research bridges Drosophila melanogaster and human physiology to investigate intestinal stem cell repair mechanisms after tissue damage. Education: BS in Pharmacy from National Defense University, Taipei (1984); PhD in Biochemistry from University of Iowa (1989) Postdoctoral training: University of California, San Diego (1991-1994) His work focuses on intestinal stem cell biology , exploring how these cells respond to injury through insulin signaling and genetic pathways. By studying the simple cellular organization of Drosophila midgut , he identifies genes critical for stem cell division and tissue repair, offering insights into human conditions like inflammatory bowel disease and GI cancers. Key publication trends include genetic screens , signaling pathways , and immune response mechanisms . His studies on Toll receptors , Hippo pathway , and YAP/TAZ highlight cross-species regulatory networks. Scientific Awards : Hoffmann-LaRoche Fellow (1991-1994) Leukemia Society of America Scholar Award (1996-2001) Ip's lab offers rotation projects and postdoctoral positions to investigate genetic regulators of stem cell division and RNAi-based screens . His interdisciplinary collaborations span biochemistry , molecular biology , and cellular imaging .

• Chaperone-Mediated Autophagy
• Autophagy
• Aging
• +۳ مورد دیگر

Esperanza Arias-Perez, Ph.D., is a researcher at the Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine. Her work focuses on molecular mechanisms of autophagy, with emphasis on chaperone-mediated processes in aging, cancer, and neurodegeneration. She leads collaborative studies exploring therapeutic applications of autophagy modulation. Research Interests: Her investigations span: Chaperone-mediated autophagy in aging and cellular quality control Autophagy dysregulation in cancer progression and neurodegeneration Sex-specific and tissue-specific autophagy mechanisms Therapeutic targeting of autophagic pathways Publication Trends: Her 24 publications predominantly analyze autophagy's role in cellular homeostasis, with recent work (2021-2025) highlighting: Links between autophagy, aging hallmarks, and cancer Cell-type-specific autophagy mechanisms in disease contexts Therapeutic strategies for glioma, neurodegeneration, and age-related pathologies

Andrew Aguirreمشاهده پروفایل

دانشیار

• Translational Oncology
• Pancreatic Cancer
• KRAS-driven Cancers
• +۷ مورد دیگر

Andrew Aguirre, MD, PhD, is an Associate Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute, where he also serves as an Investigator in the Hale Family Center for Pancreatic Cancer Research. He is an Associate Member of the Broad Institute of MIT and Harvard, reflecting his interdisciplinary research at the intersection of genomics and oncology. Research Interests: Translational Oncology Pancreatic Cancer Biology KRAS-driven Malignancies Functional Genomic Screens Therapeutic Resistance Mechanisms Precision Medicine and Biomarker Discovery Dr. Aguirre's lab integrates genomic, molecular, and cellular approaches to uncover vulnerabilities in pancreatic cancer, particularly focusing on synthetic lethality with KRAS mutations. His work leverages patient-derived organoids and genetically engineered mouse models to translate findings into novel therapies. The 15 most recent publications highlight a consistent focus on KRAS inhibition, resistance mechanisms, tumor heterogeneity, and the tumor microenvironment. His research spans functional genomics, transcriptomics, and therapeutic development, with a strong emphasis on translating discoveries into clinical applications for pancreatic and other RAS-driven cancers. Scientific Awards & Recognition: Lubin Family Foundation Scholar (awarded to lab member Dan Gui) Promotion to Associate Professor of Medicine (2024) Co-Director, DFCI Center for RAS Therapeutics (2025) Dr. Aguirre actively mentors a dynamic team of postdoctoral fellows, research technicians, and students, fostering a collaborative environment that bridges basic science and clinical oncology. His lab has ongoing collaborations with clinical and computational researchers, supporting a multidisciplinary approach to cancer research. The Aguirre Lab is also engaged in training the next generation of scientists through co-op programs and summer internships. Laboratory & Team: Aguirre Lab for Pancreatic Cancer Research, Dana-Farber Cancer Institute Co-Director, DFCI Center for RAS Therapeutics Collaborations with Dr. William C. Hahn, Dr. Brian Wolpin, and others Active participation in AACR and other major oncology conferences